

Kirkland Advises Amicus Therapeutics on \$4.8 Billion Sale to BioMarin

Overview of a Landmark Biopharmaceutical Transaction

The biopharmaceutical industry continues to experience significant consolidation as companies seek to expand rare disease portfolios, strengthen pipelines, and achieve long-term growth. One of the most notable developments in this space is the **\$4.8 billion sale of Amicus Therapeutics to BioMarin**, a transaction advised by **Kirkland & Ellis**, one of the world's leading global law firms.

This high-profile deal underscores the strategic importance of rare disease therapies, the increasing value of specialized biotech innovation, and the role of elite legal advisors in navigating complex mergers and acquisitions. The transaction positions BioMarin to expand its footprint in genetic and neuromuscular disorders while providing Amicus stakeholders with substantial value realization.

The Strategic Role of Kirkland & Ellis

Kirkland & Ellis played a central advisory role in the transaction, providing legal counsel to Amicus Therapeutics throughout the sale process. Known for its deep expertise in **life sciences M&A, private equity, and complex corporate transactions**, Kirkland guided Amicus through deal structuring, negotiation, regulatory considerations, and shareholder matters.

The firm's involvement highlights its continued dominance in large-scale healthcare and biotechnology transactions, particularly those involving cross-border operations, intellectual property assets, and regulatory scrutiny. Kirkland's advisory work ensured that the transaction aligned with Amicus's strategic objectives while maximizing value for shareholders.

About Amicus Therapeutics

Amicus Therapeutics is a biotechnology company focused on developing treatments for rare and devastating genetic diseases. The company has built its reputation on innovative science

aimed at addressing unmet medical needs, particularly in conditions with limited or no existing therapies.

Over the years, Amicus has invested heavily in research and development, assembling a portfolio of therapies designed to improve patient outcomes in complex disorders. Its work in precision medicine and disease-modifying treatments made the company an attractive acquisition target for larger pharmaceutical players seeking to enhance their rare disease offerings.

BioMarin's Growth Strategy and Rationale for the Acquisition

BioMarin has long been recognized as a leader in rare disease therapeutics. The acquisition of Amicus Therapeutics for **\$4.8 billion** represents a strategic move to complement BioMarin's existing portfolio and reinforce its commitment to serving patient populations with high unmet needs.

By acquiring Amicus, BioMarin gains access to:

- Expanded research and development capabilities
- A broader pipeline of rare disease therapies
- Specialized scientific talent and intellectual property
- Opportunities for operational and commercial synergies

The transaction reflects BioMarin's long-term vision of sustainable growth through targeted acquisitions that align with its scientific focus and mission-driven culture.

Financial and Market Implications

The \$4.8 billion valuation places this transaction among the most significant biotech deals in recent years. It signals strong investor confidence in the rare disease sector, even amid broader market volatility.

For Amicus shareholders, the sale provides immediate liquidity and value recognition. For BioMarin, the acquisition represents a calculated investment in future revenue streams and pipeline diversification.

The deal also sends a broader message to the biotech market: **innovative science in rare diseases continues to command premium valuations**, especially when supported by strong clinical data and clear commercialization pathways.

Regulatory and Transactional Considerations

Large biopharmaceutical acquisitions typically involve rigorous regulatory review, particularly in areas related to competition, drug pricing, and intellectual property rights. Kirkland's advisory role included navigating these complexities to ensure compliance and facilitate a smooth transaction process.

Such deals often require coordination across multiple jurisdictions, engagement with regulatory authorities, and careful management of disclosure obligations. The successful progression of this transaction reflects the depth of planning and legal precision involved.

Impact on the Rare Disease Ecosystem

Beyond the companies directly involved, the sale of Amicus Therapeutics to BioMarin has broader implications for the rare disease ecosystem:

- **Patients** may benefit from increased resources dedicated to therapy development and commercialization.
- **Researchers and clinicians** gain support from a larger organization with global reach.
- **Biotech innovators** see renewed validation that focused, mission-driven research can lead to meaningful exits.

The transaction reinforces the idea that consolidation, when strategically aligned, can accelerate innovation and patient access.

Kirkland's Continued Leadership in Life Sciences M&A

Kirkland & Ellis has consistently ranked among the top legal advisors for mergers and acquisitions in the healthcare and life sciences sectors. Its role in the Amicus–BioMarin transaction further solidifies its reputation for handling high-value, high-complexity deals.

The firm's integrated approach—combining corporate law, regulatory expertise, intellectual property, and litigation readiness—makes it a preferred advisor for biotech companies navigating transformational events.

Frequently Asked Questions

What is the value of the Amicus Therapeutics sale to BioMarin?

The transaction values Amicus Therapeutics at approximately **\$4.8 billion**.

Who advised Amicus Therapeutics on the sale?

Amicus Therapeutics was advised by **Kirkland & Ellis**, a leading global law firm.

Why did BioMarin acquire Amicus Therapeutics?

BioMarin acquired Amicus to expand its rare disease portfolio, strengthen its research pipeline, and support long-term strategic growth.

What does this deal mean for the biotech industry?

The transaction highlights ongoing consolidation in biotech and strong demand for rare disease innovation.

How does the acquisition impact patients?

The deal has the potential to accelerate development and global access to therapies for rare genetic diseases.

Conclusion

The \$4.8 billion sale of Amicus Therapeutics to BioMarin, advised by Kirkland & Ellis, stands as a defining moment in the biopharmaceutical sector. It reflects the enduring value of rare disease innovation, the strategic importance of well-aligned acquisitions, and the critical role of experienced legal counsel in executing transformative transactions.

As the biotech industry continues to evolve, deals of this magnitude will shape the future of healthcare innovation—driving investment, collaboration, and progress for patients worldwide.